vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and FEDERAL AGRICULTURAL MORTGAGE CORP (AGM). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $107.5M, roughly 1.3× FEDERAL AGRICULTURAL MORTGAGE CORP). On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 6.1%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 7.1%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
The Federal Agricultural Mortgage Corporation, also known as Farmer Mac, is a stockholder-owned, federally chartered corporation established by the U.S. Congress in 1988 under the Agricultural Credit Act of 1987. It was created to establish a secondary market for agricultural real estate and housing mortgage loans, to increase liquidity and the availability of long-term, stable credit for farmers, ranchers, and rural communities.
ADMA vs AGM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $107.5M |
| Net Profit | $49.4M | — |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 56.3% |
| Net Margin | 35.5% | — |
| Revenue YoY | 18.4% | 6.1% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | $3.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $107.5M | ||
| Q3 25 | $134.2M | $104.0M | ||
| Q2 25 | $122.0M | $102.6M | ||
| Q1 25 | $114.8M | $94.3M | ||
| Q4 24 | $117.5M | $101.3M | ||
| Q3 24 | $119.8M | $90.3M | ||
| Q2 24 | $107.2M | $89.9M | ||
| Q1 24 | $81.9M | $93.7M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $55.0M | ||
| Q2 25 | $34.2M | $54.8M | ||
| Q1 25 | $26.9M | $49.7M | ||
| Q4 24 | $111.9M | $56.5M | ||
| Q3 24 | $35.9M | $49.8M | ||
| Q2 24 | $32.1M | $47.1M | ||
| Q1 24 | $17.8M | $53.7M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 56.3% | ||
| Q3 25 | 38.0% | 64.1% | ||
| Q2 25 | 35.1% | 63.8% | ||
| Q1 25 | 30.4% | 66.9% | ||
| Q4 24 | 32.6% | 67.5% | ||
| Q3 24 | 33.1% | 69.0% | ||
| Q2 24 | 36.6% | 65.9% | ||
| Q1 24 | 26.7% | 72.8% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | 52.9% | ||
| Q2 25 | 28.1% | 53.4% | ||
| Q1 25 | 23.4% | 52.6% | ||
| Q4 24 | 95.2% | 55.8% | ||
| Q3 24 | 30.0% | 55.2% | ||
| Q2 24 | 29.9% | 52.4% | ||
| Q1 24 | 21.7% | 57.4% |
| Q4 25 | $0.20 | $3.69 | ||
| Q3 25 | $0.15 | $4.44 | ||
| Q2 25 | $0.14 | $4.48 | ||
| Q1 25 | $0.11 | $4.01 | ||
| Q4 24 | $0.45 | $4.62 | ||
| Q3 24 | $0.15 | $3.86 | ||
| Q2 24 | $0.13 | $3.68 | ||
| Q1 24 | $0.08 | $4.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | $30.8B |
| Stockholders' EquityBook value | $477.3M | $1.7B |
| Total Assets | $624.2M | $35.4B |
| Debt / EquityLower = less leverage | 0.15× | 17.93× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | $842.1M | ||
| Q2 24 | $88.2M | $923.0M | ||
| Q1 24 | $45.3M | $745.1M |
| Q4 25 | $72.1M | $30.8B | ||
| Q3 25 | $72.4M | $29.2B | ||
| Q2 25 | — | $28.9B | ||
| Q1 25 | — | $28.0B | ||
| Q4 24 | $72.3M | $27.5B | ||
| Q3 24 | — | $27.2B | ||
| Q2 24 | — | $26.8B | ||
| Q1 24 | — | $26.8B |
| Q4 25 | $477.3M | $1.7B | ||
| Q3 25 | $431.2M | $1.7B | ||
| Q2 25 | $398.3M | $1.5B | ||
| Q1 25 | $373.4M | $1.5B | ||
| Q4 24 | $349.0M | $1.5B | ||
| Q3 24 | $231.9M | $1.5B | ||
| Q2 24 | $188.3M | $1.5B | ||
| Q1 24 | $153.7M | $1.5B |
| Q4 25 | $624.2M | $35.4B | ||
| Q3 25 | $568.7M | $33.4B | ||
| Q2 25 | $558.4M | $33.0B | ||
| Q1 25 | $510.6M | $31.8B | ||
| Q4 24 | $488.7M | $31.3B | ||
| Q3 24 | $390.6M | $30.6B | ||
| Q2 24 | $376.4M | $30.2B | ||
| Q1 24 | $350.9M | $29.8B |
| Q4 25 | 0.15× | 17.93× | ||
| Q3 25 | 0.17× | 17.31× | ||
| Q2 25 | — | 18.70× | ||
| Q1 25 | — | 18.39× | ||
| Q4 24 | 0.21× | 18.48× | ||
| Q3 24 | — | 18.60× | ||
| Q2 24 | — | 17.87× | ||
| Q1 24 | — | 18.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $80.1M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | 0.0% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $80.1M | ||
| Q3 25 | $13.3M | $74.2M | ||
| Q2 25 | $21.1M | $-47.7M | ||
| Q1 25 | $-19.7M | $-49.8M | ||
| Q4 24 | $50.2M | $612.6M | ||
| Q3 24 | $25.0M | $-44.4M | ||
| Q2 24 | $45.6M | $56.1M | ||
| Q1 24 | $-2.2M | $233.3M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | $607.4M | ||
| Q3 24 | $24.0M | $-44.4M | ||
| Q2 24 | $43.6M | $52.6M | ||
| Q1 24 | $-4.6M | $231.7M |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | 599.8% | ||
| Q3 24 | 20.0% | -49.2% | ||
| Q2 24 | 40.7% | 58.5% | ||
| Q1 24 | -5.6% | 247.3% |
| Q4 25 | 0.8% | 0.0% | ||
| Q3 25 | 10.7% | 0.0% | ||
| Q2 25 | 2.0% | 0.0% | ||
| Q1 25 | 4.1% | 0.0% | ||
| Q4 24 | 2.3% | 5.2% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 4.0% | ||
| Q1 24 | 2.9% | 1.7% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 1.35× | ||
| Q2 25 | 0.62× | -0.87× | ||
| Q1 25 | -0.73× | -1.00× | ||
| Q4 24 | 0.45× | 10.84× | ||
| Q3 24 | 0.70× | -0.89× | ||
| Q2 24 | 1.42× | 1.19× | ||
| Q1 24 | -0.12× | 4.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
AGM
Segment breakdown not available.
